Purpose of review Natural killer (NK) cells are innate lymphoid cells specialized to eliminate malignant cells via direct cytotoxicity and immunoregulatory cytokine production. As such, NK cells are ideal as cellular therapy for cancer patients, and several studies have provided proof of principle that adoptively transferred NK cells can induce remissions in patients with leukemia. A clear understanding of the mechanisms underlying NK cell antitumor responses, including target cell recognition, activation status, and negative regulatory signals will improve NK cellular therapy for cancer patients.
INTRODUCTION
For over a century, it has been understood that the immune system is involved in controlling tumor growth [1] . Cancer immunotherapy strategies seek to harness the immune system's implicit ability to recognize and eliminate malignant cells, mediated by T cells, natural killer (NK) cells, NK T cells, B cells, dendritic cells, and macrophages [2] . As the original immune-based cellular therapy, allogeneic hematopoietic cell transplantation (HCT) has provided long-term, disease-free survival to patients with hematologic cancers [3] . HCT procedure suppresses a patient's immune system to allow engraftment of the allogeneic donor's immune system, which in turn eliminates 'foreign' cancer cells, commonly referred to as a graft-versus-leukemia effect. The drawback of this treatment approach is the recognition of normal patient cells as 'foreign', thereby causing graft-versus-host disease (GVHD), a major life-threatening complication. Thus, one rational approach to improve allogeneic HCT is to isolate specific antitumor immune cells, primarily T and NK cells, and utilize them for cell-based therapy. Indeed, the success of chimeric antigen receptor (CAR)-modified T cells for the treatment of B cell malignancies has demonstrated the promise of this reductionist cellular immunotherapy approach. Similarly, NK cells have been isolated from allogeneic donors and utilized to induce remissions, primarily in patients with acute myeloid leukemia (AML).
NK cells are innate lymphoid cells that circulate through most tissues, and are specialized to eliminate virus-infected and malignantly transformed target cells [4, 5] . NK cells contribute to cancer immunoediting [6] , and are frequently deficient or dysfunctional in cancer patients [7] [8] [9] , suggesting that NK cells represent a significant immunoevasion requirement for cancer genesis and progression. Further, a large epidemiologic study demonstrated that decreased NK cell function predicted for an increased risk of developing cancer [10] . In the setting of allogeneic HCT, human leukocyte antigen (HLA)-haploidentical NK cells can recognize AML blasts, which predicts for improved outcomes in high-risk AML [11] [12] [13] [14] . Adoptive NK cell therapy studies utilizing the HLA disparity between the donor NK cells and patient AML to target NK cells to blasts show promise [15,16 && ]. Further, immunogenetic studies of killer-cell immunoglobulin-like receptors (KIR) in patients who have undergone HCT have correlated certain KIR haplotypes or activating receptor expression with disease relapse [17] [18] [19] . Some parameters are currently being investigated to improve NK cell adoptive immunotherapy, including the donor cell source, the use of largescale ex-vivo expansion, use of off-the-shelf cell lines, and NK cell differentiation from progenitors [20] [21] [22] [23] . Moreover, strategies are now being tested to optimize NK cell responses, including targeting NK cells more effectively to the tumor, enhancing NK cell antitumor functional status, and removing inhibitory signals or cells [23] . The focus of this review is to summarize recent advancements in the adoptive NK cellular therapy of cancer, and highlight promising NK cell immunotherapy combination strategies.
WHAT IS A NATURAL KILLER CELL?
NK cells are innate lymphoid cells that can recognize and eliminate malignant cells. NK cell functions that are responsible for tumor surveillance and clearance include cytokine/chemokine secretion and cytotoxicity [4, 5, 24] . These cytokines (e.g., IFN-g and tumor necrosis factor) and chemokines (e.g., macrophage inflammatory protein-1a) are important for shaping the immune response to the tumors and for recruiting additional effector cells to the site of malignancy [4] . NK cells also release perforin and granzymes into specialized cytotoxic synapses to induce target cell death. Following activation, NK cells may also express the death receptor ligands TNF-related apoptosisinducing ligand and Fas ligand, which bind to their receptors on target cells to trigger apoptosis. Human NK cells are phenotypically identified as CD56 þ cells lacking T (CD3, T cell receptor) and B (CD19) cell lineage markers, constituting approximately 10% of human blood lymphocytes, and consist of two developmentally related but functionally distinct subsets of human NK cells, CD56 dim , and CD56 bright NK cells [25] .
To maintain proper tolerance to healthy tissues and effectively eliminate diseased cells, NK cells utilize germ line-encoded activating and inhibitory receptors [26] . During development, NK cells must express at least one inhibitory receptor specific for self major histocompatibility complex class I (MHC-I) to attain functional competence (e.g., licensing) [27] . In a mature, licensed NK cell, the balance of signals received through these receptors determines the fate of the engaged cell, in which more activating receptor signaling results in target killing and cytokine production. NK cells recognize diseased cells that have lost inhibitory receptor ligand expression ('missing self') and upregulated activating receptor ligands ('abnormal or induced self'). KIR and C-type lectin inhibitory receptors (CD94/NKG2A) recognize MHC-I and MHC-I-like molecules that are expressed on most normal healthy tissues, and provide the negative signals that prevent NK cell autoimmunity. Activating receptors expressed by NK cells, such as NKG2D, NKp46, and natural cytotoxicity receptors recognize ligands that are upregulated on stressed or malignant cells [26] . NK cell receptors are variably and stochastically expressed on individual NK cells, resulting in thousands of NK cell specificities [28 & ]. NK cell responses are not static; activated NK cells upregulate both inhibitory molecules (e.g., lymphocyte-activation gene 3, T cell immunoglobulin mucin-3, programmed cell death protein 1) and coactivating receptors (e.g., CD137). Although induced inhibitory receptors are important in resolving a normal immune response and protecting healthy tissues, they also represent a means by which malignant cells evade NK cell responses [29] [30] [31] [32] [33] . While immune checkpoints are well defined in T cell antitumor responses, relevant activation-induced NK cell inhibitory checkpoints remain under investigation. In addition, recent studies revealed that NK cells can exhibit memory of prior activation [34] , and NK cell memory is an area of active investigation [35] . Thus, NK cells are KEY POINTS NK cell adoptive immunotherapy may induce CRs in patients with AML.
NK cell recognition and targeting may be enhanced using therapeutic mAbs, bi and trispecific agents, and CARs.
specialized effectors poised to respond to malignant cells, but in many diseases, require modulation of trigger/recognition, functional capacity, or negative regulators for an optimal response.
ADOPTIVE NATURAL KILLER CELL IMMUNOTHERAPY
As donor NK cell alloreactivity against leukemia correlated with improved clinical outcomes in AML patients with HLA-haploidentical HCT [11] [12] [13] [14] , most studies of NK cell adoptive immunotherapy have been performed in this disease. The recognition of an AML blast was linked to functionally competent NK cells triggered via missing-self or induced/abnormal-self signaling [17] [18] [19] . In the first clinical trial investigating NK cell adoptive transfer outside of HCT, Miller et al. enriched NK cells by depleting T cells ($40% NK cells in the final product), activated overnight with IL-2, and administered these cells to lymphodepleted (fludarabine/cyclophosphamide) AML patients [15] . Key parameters of this and other reported studies of NK cellular therapy are summarized in Table 1 . Overall, five of 19 (26%) of AML patients achieved a complete remission (CR) on this trial. Curti et al. administered purified CD56 þ CD3 À NK cells from HLA-haploidentical donors selected for a KIR-ligand mismatch using a similar treatment protocol. Of the five patients with active AML, patient (20%) obtained a CR [14] . More recently, Bachanova et al. reported a series of patients treated with modifications of the Miller et al. platform, and demonstrated that the provision of IL-2-diptheriatoxin to deplete regulatory T cells (Tregs) enhanced NK cell expansion and increased the frequency of CR (50%). General conclusions from these studies included: lymphodepletion is important for donor NK cell expansion and resulted in increased host IL-15 production, in-vivo expansion of donor NK cells correlated with AML CR frequencies, allogeneic NK cells did not cause GVHD, and patient Tregs limit NK cell expansion and antileukemia activity in vivo. Multiple groups are examining alternative sources of NK cells, such as ex-vivo expansion, differentiation from progenitors, and even immortalized NK cell lines [21, [36] [37] [38] [39] . Although these studies provide proof of principle that allogeneic NK cell adoptive transfer may induce remissions in leukemia patients, it is clear that new, complementary approaches are needed to achieve lasting responses in patients ( Table 2) .
There remain a large number of open questions in the field, including the optimal setting in which to administer adoptive NK cell therapy. Although NK cell adoptive immunotherapy has the benefit of no GVHD, the 'window of opportunity' for NK cells Natural killer cell cancer immunotherapy Berrien-Elliott et al. to clear leukemia is a few weeks, as host T cells eliminate allogeneic donor NK cells as they recover from fludarabine/cyclophosphamide . In contrast, adding NK cell infusions to HCT procedures may allow for persistence in the host, enhance graftversus-leukemia effect, and reduce GVHD, but does not address the key adverse events associated with the HCT per se. Thus, the most recent research efforts have investigated multiple approaches to enhance NK cell antitumor responses, which may have implications in NK cell adoptive immunotherapy in either setting, and may also be used to stimulate endogenous patient NK cell responses. The remainder of the review focuses on progress in the three major strategies to enhance NK cellmediated tumor clearance.
PROVIDING A TRIGGER: ENHANCING NATURAL KILLER CELL TUMOR RECOGNITION
Although initial studies utilized KIR-ligand mismatch to facilitate donor NK cell recognition of recipient leukemia, advances in our understanding of NK cell triggering via CD16 by monoclonal antibody (mAb) therapies has led to the development of novel single-chain variable fragments (scFv) fusion proteins, designed to enhance targeting the NK cell to the tumor. Bispecific killer cell engagers (BiKE) and trispecific killer cell engagers that cross-link CD16 expressed on NK cells and 1-2 tumor antigens on target cells have been reported in preclinical studies [50] . The CD16xCD33 BiKE triggered NK cells via CD16 to kill and produce cytokines in response to CD33-expressing cell lines and primary leukemia samples in vitro [50] . Gleason ]. AFM13 is a tetravalent chimeric antibody construct that contains two binding domains for CD16A, the NK cell specific isoform of the CD16 receptor and CD30, which is expressed on hematologic malignancies, including Hodgkin lymphoma. In this study, patients were treated with escalating doses of AFM13 (0.01-7.0 mg/kg, three patients per dose) administered once a week for 4 weeks. AFM13 was well tolerated, and three of 26 patients experienced a partial response. Furthermore, the authors demonstrated enhanced activation marker expression on NK cells after AFM13 infusion providing a proof of principle that NK cells can be targeted and enhanced by AFM13 in vivo. By specifically using the CD16A scFv, the large sink of CD16 þ non-NK cells is eliminated (e.g., CD16B þ neutrophils), potentially improving the potency of this class of agents. Finally, a number of clinical mAbs partially rely on antibody dependent cellular cytotoxicity (ADCC) mediated tumor clearance, including trastuzumab, rituximab, and cetuximab [52,53 & ,54,55] . Efforts are being made to optimize mAbs to enhance ADCC and antibody-dependent cytokine release (ADCR) by NK cells [42, 56] . Because these responses are dependent on immunoglobulin G (IgG)Fc interaction with Fc receptors, de Romeuf et al. generated a chimeric mAb, which promoted optimal FcgRIIIA (CD16A) binding and signaling [56] . In two separate studies, Le Garff-Tavernier et al. compared ADCC of chronic lymphocytic leukemia or lymphoplasmacytic lymphoma opsonized with the Fc-optimized anti-CD20 mAb, ublituximab, or with the first-generation anti-CD20 antibody, rituximab [43,57 & ]. In both studies, NK cell engagement with the ublituximab resulted in increased degranulation and target killing compared with rituximab [43,57 & ]. All of these agents rely on CD16-triggered NK cell functions; however, a number of additional activating receptors (e.g., NKG2D) expressed by NK cells could be targeted in a similar fashion, thereby producing potent activating signals to enhance NK cell effector functions. Apart from these antibody-type targeting agents, there is interest in using CAR-modified NK cells for enhancing tumor specificity [44,45 & ,58,59] . Haploidentical NK cells could be enriched from donor peripheral blood mononuclear cells, transduced to express tumorspecific CAR with NK cell activating receptor signaling domains (i.e., DAP10 and DAP12) [45 & ]. Because aplasia of normal hematopoietic stem cells and progenitors induced by long-lasting CAR T cells is currently one of the major hurdles in successfully using this technology for treating cancers like AML [60, 61] , the shorter persistence of allogeneic CAR NK cells may provide a viable alternative to CAR T cells. cytokine receptors by NK cells provides opportunities to use cytokines for immunomodulation [62] . Classically, IL-2 has been used to activate and support NK cells in vivo for patients receiving NK cell adoptive therapy. One major drawback is the exquisite sensitivity of Tregs to IL-2 via their high-affinity IL-2Rabg, which may expand and limit NK cell responses [62] . IL-15 is a critical cytokine for NK cell homeostasis and function, and has been a longstanding attractive alternative to IL-2 to augment NK cell and CD8 T cell number and function [48, 63, 64] . Recently, the results of a first-in-human phase 1 clinical trial of recombinant human interleukin (rhIL)-15 administered to advanced cancer patients demonstrated safety with clear NK and T cell immunomodulation [65 && ]. This study provides the first evidence that IL-15-based agents are feasible in the clinic with favorable adverse event profiles at biologically active doses. Alternative forms of IL-15based therapy have also been developed and are now in clinical trials. ALT-803 is an IL-15 superagonist mutein complexed with a fusion of IL-15Ra sushi domains to an IgG1 Fc domain, resulting in increased stability and in-vivo half-life of this protein complex [66 && ]. ALT-803 is currently being evaluated in a number of clinical trials in cancer patients, and more recently, in combination with therapeutic mAbs. IL-12, IL-18, and IL-21 are also being explored as NK cell activating cytokine adjuvants [62] . Beyond the scope of this review, several groups are utilizing cytokines and artificial stimulator cells to expand and activate NK cells prior to adoptive transfer (Table 3) [62, 67] .
PRESS THE GAS PEDAL: FUNCTION-ENABLING NATURAL KILLER CELLS
Recent advances in NK cell biology have identified that NK cells exhibit a memory of prior activation [34] , which includes enhanced responses to leukemia. For example, brief IL-12, IL-15, and IL-18 combined preactivation of human NK cells resulted in differentiation of memory-like NK cells [68, 69 & ], with enhanced IFN-g secretion and cytotoxicity upon restimulation with cytokines or tumor targets [35, 68] . This approach is now being tested in a firstin-human study of cytokine-induced memory-like NK cells in patients with relapsed or refractory AML (NCT01898793). Phase 1 testing of haploidentical NK cells primed ex vivo with CTV-1 lysate has been completed, and preliminary reports show that this approach is safe (NCT01520558) [70] . Lenalidomide is an immunomodulatory agent that has been demonstrated to enhance ADCC by NK cells [46, 71] . Multiple trials are utilizing lenalidomide in combination with antitumor mAbs to enhance NK cellmediated ADCC, and to improve clinical outcomes for patients (Table 2 ). In addition to targeting NK cells to tumors, mAbs can also signal through costimulatory receptors to improve NK cell function.
Using anti-41BB agonistic antibodies is one such strategy which is currently being tested in the clinic ( 
TAKE YOUR FOOT OFF THE BRAKE: BLOCKING NATURAL KILLER CELL INHIBITION
Similar to other immune cells, NK cells have endogenous checks on their activity. To fully optimize NK cell antitumor responses in vivo, approaches are required to limit NK cell suppression, either from inhibitory molecules expressed by the NK cell (i.e., KIR) [73] , or by suppressor cell types (i.e., Tregs, myeloid derived suppressor cells) [74, 75] ( Fig. 1) . As previously mentioned, Tregs represent one obstacle to proper NK cell expansion after adoptive therapy plus IL-2 [47] . To limit Tregs during IL-2 administration, Bachanova et al. utilized an IL-2 diphtheria toxin fusion protein to selectively deplete recipient Tregs [16 && ]. In addition to extrinsic NK cell inhibition by regulatory cells, inhibitory receptors expressed by NK cells can also suppress their activities, such as the constitutively expressed KIR or NKG2A, as well as the induced coinhibitory receptors (i.e., T cell immunoglobulin mucin-3, programmed cell death protein 1) [26, 76] . IPH2101 are mAb blocking common KIRs that bind to HLA-C alleles with the aim of disrupting the inhibitory HLA-KIR signal and enhancing NK cell function [77,78,49 & ]. Initial clinical studies using IPH2101 did not demonstrate any major responses while using this as a single agent [77, 78] . In a recent study, IPH2101 combined safely with lenalidomide in the absence of steroids with objective responses observed in patients with relapsed/refractory multiple myeloma [49 & ], providing support for the concept that combined immunotherapy strategies are required to unleash the most potent NK cell response.
CONCLUSION
The great promise of NK cell antitumor immune effects continues to expand as basic aspects of their biology are unraveled and translated to the clinic. Adoptively transferred NK cells mediate antileukemia responses and can result in remissions, but many open questions remain regarding optimal purification, ex-vivo manipulations, and in-vivo support tactics. New immunotherapy approaches that combine allogeneic NK cell therapy with strategies to improve targeting/triggering, augment antitumor responses, and limit inhibition will be the key to enhance the efficacy of NK cell adoptive therapy to a wider variety of malignancies. . Combinatorial strategies to improve NK cell adoptive immunotherapy. NK cell adoptive therapy can be improved by combination approaches aimed at enhancing NK cell tumor specificity, enhancing NK cell effector capacity, and by reducing NK cell inhibition. Tumor specificity can be increased by utilizing bispecific killer engagers or ADCC-optimized, tumor-specific monoclonal antibodies. NK cell effector capacity can be improved by in-vitro preactivation with cytokines as well as in vivo with cytokine support, either with recombinant cytokines or with cytokine receptor super-agonists (e.g., ALT-803). Furthermore, activating receptor agonists can also be employed in vivo to improve NK cell activation and effector responses. Antibody checkpoint blockade therapy specific for inhibitory receptors expressed by NK cells will limit cell intrinsic immunosuppression. Finally, efforts to deplete regulatory T cells during NK cell adoptive therapy, for example using IL-2 diphtheria toxin fusion protein, are promising and currently under investigation. NK, natural killer cells.
